In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Show Me the Money: Why Companies Overpay MCOs--and How They Can Stop

Executive Summary

To get on formularies, drug companies pay MCOs too much in rebates and get too little market share in return. But "fair share" analysis can help yield big revenue gains as well as giving drug companies the tools to make business-improving tradeoffs within their product portfolios. Key analyses and related interventions can help return to manufacturers some of the market power and negotiating leverage that is shifting from pharma companies to MCOs.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts